Arkolith/Insider Trading/ESPR/Form 4

Koenig Sheldon L.

President and CEO, DirectorEsperion Therapeutics, Inc. (ESPR) · full profile →Form 4 · filed Mar 17, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 14, 2025Grant(A)840K—$01.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 14, 2025Grant(A)753K—$0753K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-013199) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML